Themis Medicare Approves Financial Results, Warrant Issue, and Key Management Changes
Themis Medicare Limited reported its Q3 FY26 results. The Board approved the issuance of convertible equity warrants to promoters, potentially up to 4.99% of share capital. Mr. Pradeep M. Chandan resigned as Company Secretary, and Mr. Nagraj Mogaveera was appointed as Interim Company Secretary. An inter-se transfer of 3% in Gujarat Themis Biosyn Limited was also approved.
The proposed issuance of convertible equity warrants could lead to future equity dilution or fundraising, impacting the capital structure. Management changes and financial results are also material but routine.
The announcement includes routine financial results, management changes, and a proposal for future fundraising, which are standard corporate actions. While the warrant issuance could be seen positively, it is still a proposal and subject to approvals.
Themis Medicare Limited's Board of Directors met on February 13, 2026, approving the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company also noted the resignation of Mr. Pradeep M. Chandan as Company Secretary, Compliance Officer & Key Managerial Personnel (KMP) effective February 13, 2026.
Following this, the Board approved the appointment of Mr. Nagraj Mogaveera as Interim Company Secretary, Compliance Officer & KMP, effective February 14, 2026. Mr. Mogaveera is a qualified Company Secretary with 8 years of experience.
Furthermore, the Board approved a proposal for the issuance of convertible equity warrants to Promoter/Promoter Groups via preferential allotment, subject to regulatory and shareholder approvals. A Preferential Issue Committee has been formed to finalize the terms. The proposed issue could amount to up to 4.99% of total shareholding, equivalent to 45,95,795 equity shares.
Additionally, the company approved an inter-se transfer of up to 3% of the paid-up equity share capital of Gujarat Themis Biosyn Limited (GTBL) held by Themis Medicare Limited, within the Promoter/Promoter Group. This transfer will be executed at the prevailing market price and will not alter the overall Promoter and Promoter Group shareholding or control.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.